ADMA Biologics Inc (ADMA) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Total Cash From Operating Activities Chart for ADMA Biologics Inc

ADMA Biologics Inc (ADMA) operating cash flow for FY2025 was USD 50.4M, a -57.5% change from FY2024. ADMA Biologics Inc's operating cash flow moved from USD -23.6M in 2006 to USD 50.4M in 2025 over 19 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$2.39B
Implied Share Price
$10.68
Enterprise Value
$2.24B
Revenue (TTM)
$512.28M
EBITDA
$224.19M
Profit Margin
32.98%
Trailing P/E
15.26
Forward P/E
9.78
Price/Book (MRQ)
5.32
Price/Sales (TTM)
4.67
EV/EBITDA
9.61
EV/Revenue
4.37
Dividend Yield
—
Book Value
$1.81
Free Cash Flow (FY2025)
$27.82M
Free Cash Flow Yield
1.16%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.